<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911869</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-818-201</org_study_id>
    <secondary_id>C4221006</secondary_id>
    <secondary_id>2018-004555-21</secondary_id>
    <nct_id>NCT03911869</nct_id>
  </id_info>
  <brief_title>An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis</brief_title>
  <acronym>POLARIS</acronym>
  <official_title>A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized open-label Phase 2 study to assess the safety, efficacy and&#xD;
      pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in&#xD;
      patients with BRAFV600-mutant melanoma with brain metastasis. Approximately 100 patients will&#xD;
      be enrolled, including 9 patients in a Safety Lead-in of the high-dose treatment arm. After a&#xD;
      Screening Period, treatment will be administered in 28-day cycles and will continue until&#xD;
      disease progression, unacceptable toxicity, withdrawal of consent, start of subsequent&#xD;
      anticancer therapy, death.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Lead-in: Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Lead-in: Incidence and severity of adverse events (AEs)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Lead-in: Incidence of dose modifications due to AEs</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Lead-in: Incidence of treatment discontinuations due to AEs</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Brain metastasis response rate (BMRR) per modified Response Evaluation Criteria in Solid Tumors version 1.1 (mRECIST v1.1)</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extracranial response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global response rate (brain metastasis response per mRECIST v1.1 and extracranial response per RECIST v1.1)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Global response rate is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) per Investigator assessment for brain metastasis and extracranial lesions according to mRECIST v1.1 and RECIST v1.1, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain metastasis response rate (BMRR) per mRECIST v1.1 for Safety Lead-in only</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of binimetinib and its metabolite</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1 and Day 1 of Cycle 2 and Cycle 3; 28 day cycles</time_frame>
    <description>Plasma concentrations of binimetinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of encorafenib and its metabolite</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1 and Day 1 of Cycle 2 and 3; 28 day cycles</time_frame>
    <description>Plasma concentrations of encorafenib</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Standard Dose Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the standard-dose treatment arm will receive encorafenib and binimetinib in 28-day cycles.&#xD;
450 mg encorafenib orally once a day (QD)&#xD;
45 mg binimetinib orally twice a day (BID)&#xD;
Patients who are able to tolerate the standard dose during the first 4 weeks of treatment (Cycle 1) should be dose-escalated to 600 mg encorafenib QD plus 45 mg binimetinib BID provided they meet protocol-defined criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the high-dose treatment arm will receive encorafenib and binimetinib in 28-day cycles.&#xD;
300 mg encorafenib orally twice a day (BID)&#xD;
45 mg binimetinib orally twice a day (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>encorafenib</intervention_name>
    <description>taken orally</description>
    <arm_group_label>High Dose Arm</arm_group_label>
    <arm_group_label>Standard Dose Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>binimetinib</intervention_name>
    <description>taken orally</description>
    <arm_group_label>High Dose Arm</arm_group_label>
    <arm_group_label>Standard Dose Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of cutaneous melanoma with metastases to the brain.&#xD;
&#xD;
          -  Presence of B-RAF proto-oncogene, V600 mutant (BRAFV600) mutation in tumor tissue&#xD;
             previously determined by a local PCR or NGS-based assay at any time prior to Screening&#xD;
             or by a central laboratory during Screening.&#xD;
&#xD;
          -  Must have at least 1 parenchymal brain lesion ≥ 0.5 cm and ≤ 4 cm, defined as a&#xD;
             magnetic resonance imaging (MRI) contrast-enhancing lesion that may be accurately&#xD;
             measured in at least 1 dimension. (Measurable intracranial lesions that have been&#xD;
             previously irradiated and have not been shown to be progressing following irradiation&#xD;
             should not be considered as target lesions).&#xD;
&#xD;
          -  Patients may have received the following prior therapies:&#xD;
&#xD;
               1. Safety Lead-in, Phase 2 Randomized , Phase 2 Arm A Cohort 1: May have received&#xD;
                  prior local therapy for brain metastases including but not restricted to brain&#xD;
                  surgery, whole brain radiotherapy, stereotactic radiotherapy or stereotactic&#xD;
                  radiosurgery. Multiple local (brain) therapies or combinations of local therapies&#xD;
                  are allowed. For patients receiving local therapy to all brain lesions (including&#xD;
                  WBRT), progression of pre-existing lesions based on RECIST 1.1 (&gt; 20% increase in&#xD;
                  longest diameter on baseline scan) or new measurable lesions are required. For&#xD;
                  patients receiving local therapy for some but not all lesions, disease&#xD;
                  progression based on RECIST 1.1 is not required as long as there are remaining&#xD;
                  brain lesions that are measurable and not previously treated.&#xD;
&#xD;
               2. Phase 2 Arm A Cohort 2: Received no prior local therapy (e.g., brain surgery,&#xD;
                  craniotomy, SRS or SRT) for brain metastases.&#xD;
&#xD;
               3. All patients (Safety Lead-In and Phase 2): May have received prior immunotherapy.&#xD;
&#xD;
               4. All patients (Safety Lead-In and Phase 2): If receiving concomitant&#xD;
                  corticosteroids must be on a stable or decreasing dose for at least 2 weeks prior&#xD;
                  to first dose of study treatment (up to a total daily dose of 4mg of&#xD;
                  dexamethasone or equivalent).&#xD;
&#xD;
          -  An Eastern Cooperation Oncology Group Performance Status (ECOG PS) of 0 or 1 and&#xD;
             Karnofsky score ≥ 80&#xD;
&#xD;
          -  Adequate bone marrow, organ function and laboratory parameters&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic brain metastasis.&#xD;
&#xD;
          -  Uveal or mucosal melanoma.&#xD;
&#xD;
          -  History of or current leptomeningeal metastases.&#xD;
&#xD;
          -  Treatment with SRS or craniotomy within 14 days prior to start of study treatment, or&#xD;
             treatment with whole-brain radiation within 28 days prior to study treatment. Patients&#xD;
             who received local therapy should have complete recovery with no neurological&#xD;
             sequelae.&#xD;
&#xD;
          -  Either of the following:&#xD;
&#xD;
               1. Radiation therapy to non-brain visceral metastasis within 2 weeks prior to start&#xD;
                  of study treatment;&#xD;
&#xD;
               2. Continuous or intermittent small-molecule therapeutics or investigational agents&#xD;
                  within 5 half-lives of the agent (or within 4 weeks prior to start of study&#xD;
                  treatment, when half-life is unknown).&#xD;
&#xD;
          -  Patients treated in the adjuvant setting with BRAF or MEK inhibitor(s) &lt; 6 months&#xD;
             prior to enrollment. Patients who received BRAF or MEK inhibitors in the metastatic&#xD;
             setting are excluded.&#xD;
&#xD;
          -  Patient has not recovered to ≤ Grade 1 from toxic effects of prior therapy before&#xD;
             starting study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Partners</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Lions Eye Institute (RMLEI)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver CTO/CTRC - Outpatient.</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Outpatient Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute Hematology Oncology</name>
      <address>
        <city>Beaverton</city>
        <state>Oregon</state>
        <zip>97006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute Hematology Oncology - Gresham Clinic</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute Hematology Oncology - Northwest Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kniht acer Intitute Hematology Oncology - East Portland Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Center for Health &amp; Healing 2</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Center for Health and Healing</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute Hematology Oncology - Tualatin Clinic</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Médico Especializado Alexander Fleming</name>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Autónoma DE Buenosaires</state>
        <zip>CP1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia de Rosario</name>
      <address>
        <city>Rosario</city>
        <state>Santa FE</state>
        <zip>S2000KZE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion CIDEA</name>
      <address>
        <city>Caba</city>
        <zip>C1121ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crows Nest Eye Surgery</name>
      <address>
        <city>Crows Nest</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal north shore center hospital dermatology clinics</name>
      <address>
        <city>st Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Imaging</name>
      <address>
        <city>Wollstonecraft</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Universitaria Policlinico Federico II</name>
      <address>
        <city>Napoli</city>
        <state>Naples</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Cardiologia</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Farmacia</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Medicina Nucleare e Terapia Metabolica</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Melanoma, Immunoterapia Oncologica e Terapie Innovative</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Radiodiagnostica 1</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
  </removed_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=ARRAY-818-201</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRAFV600-mutant</keyword>
  <keyword>melanoma</keyword>
  <keyword>brain metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

